ClinicalTrials.gg
CompletedNCT06748157NEUROPULSEUpdated Nov 9, 2026

Non-Invasive Median Nerve Stimulation to Attenuate Atrial Tachyarrhythmias After Catheter Ablation for Atrial Fibrillation

An interventional study of CardiaCare RR2 and Sham Device in Atrial Fibrillation, sponsored by Icahn School of Medicine at Mount Sinai. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Enrollment
484th of 679
51 · median 127
Started
2024
with 53 others
No phase
405 of 993
67 open now
Registered
910th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 484th largest by enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, and was the 910th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.

The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:

  1. early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
  2. AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).

The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.

Read the detailed description

Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).

Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).

In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.

Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.

Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • AFib
  • Neuromodulation
  • Prevent AFib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ages ≥18 years
  • Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
  • Ability and willingness to sign an form.
  • Ability and willingness to use CardiaCare RR2 device, continuous monitoring, and has an available SmartPhone.

Exclusion criteria

Exclusion Criteria

  • Rheumatic heart disease
  • Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
  • Moderate to severe mitral stenosis or history of mitral valve replacement
  • Pacemaker or CRTD or any implanted electrical stimulating device
  • Unilateral or bilateral vagotomy
  • Peripheral neuropathy affecting the tested upper extremity.
  • Severe heart failure ( Class III or IV) within 90 days.
  • Recent (within 90 days) stroke or .
  • Recent (within 90 days) myocardial infarction.
  • Pregnancy or breast feeding.
  • \<1 year for any medical condition
  • Currently enrolled in another study that would interfere with this study
  • Unsuitable for participating in the study according to attending physician
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Participants with CardiaCare RR2

    Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.

    Device: CardiaCare RR2

  • Sham comparator
    Participants with Sham Device

    Sham device will be dispensed, which will create a sensation but not provide therapy

    Device: Sham Device

Interventions

  • DeviceCardiaCare RR2

    CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

  • DeviceSham Device

    Sham device will be dispensed, which will create a sensation but not provide therapy

06

What researchers measure

Primary outcomes

  1. AF/AFL occurrence

    Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG.

    Time frame: at 2-months and 6-months post-ablation procedure

Secondary outcomes

  1. Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence

    Time to first AT or AF recurrence measured by CardiaCare RR2

    Time frame: 2-month and 6-month post-ablation procedure

  2. Number of arrythmia occurrences

    Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG.

    Time frame: 2-month and 6-month post-ablation procedure

  3. Number of Atrial Arrythmia Symptoms

    Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation.

    Time frame: 6-month post-ablation procedure

  4. Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence

    Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation.

    Time frame: 6 months post-ablation

  5. Quality of Life measured using The European Heart Rhythm Association (EHRA) score

    The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms.

    Time frame: Baseline, 2-months, and 6-months

  6. Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score

    The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens.

    Time frame: Baseline, 2-months, and 6-months

  7. Change in PAC/AT/AFL before and after treatment with RR2

    Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device.

    Time frame: Baseline and 6-month post-ablation

  8. Change in Heart Rate Variability (HRV)

    Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience.

    Time frame: Baseline and 6-month post-ablation

  9. Number of ER Visits

    Time frame: 6-month post-ablation

  10. Number of Hospitalizations

    Time frame: 6-month post-ablation

  11. Number of Cardioversions

    Time frame: 6-month post-ablation

  12. Number of Ablation Re-Do's

    Time frame: 6-month post-ablation

07

Study locations

1 site
08

References and documents

Publications

  • Reddy VY, Nair DG, Turagam MK, Rosso R, Banai A, Henriques L, Strzeciwilk M, Schwartz N, Holand T, Benari A, Puzhevsky D, Ziv A, Chorin E. Noninvasive median nerve stimulation with a wearable stimulator to reduce atrial arrhythmia recurrence after atrial fibrillation ablation: The NEUROPULSE pilot. Heart Rhythm. 2026 Sep 20:S1547-5271(26)02777-3. doi: 10.1016/j.hrthm.2026.09.013. Online ahead of print. PubMed 42764112 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jul 2026, 21 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2026 → Jul 2026 and completion Oct 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 27, 2024
StartActual
Oct 2, 2024
Primary completionActual
Jul 30, 2026was Aug 2026
CompletionActual
Jul 30, 2026was Oct 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Aug 14, 2026→Jul 30, 2026 (actual)
Nov 9, 2026
Study completion
Oct 1, 2026→Jul 30, 2026 (actual)
Nov 9, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42764112 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42764112 ↗
    Primary completion Aug 14, 2026→Jul 30, 2026 (now actual)
    Study completion Oct 1, 2026→Jul 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06748157
Collaborators
Ziv HealthCare Ltd.
Responsible party
Vivek Reddy (Director EP Service, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Dec 27, 2024
Start date
Oct 2, 2024
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Nov 9, 2026

Study contacts

Vivek Reddy, MD
principal investigator · Icahn School of Medicine at Mount Sinai
Mohit Turagam, MD
principal investigator · Icahn School of Medicine at MS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion